Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

CAN-COVID, 2020 NCT04362813

canakinumab (n=227) vs. placebo (n=227)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Canakinumab
Single dose of canakinumab (450mg for body weight of 40-<60 kg, 600mg for 60-80 kg, and 750 mg for >80 kg) in 250 mL of 5% dextrose infused intravenously over 2 hours.

Control treatment

Placebo
250 mL of 5% dextrose infused intravenously over 2 hours.

Use of glucocorticoids, convalescent serum or plasma, antivirals, and anticoagulants was permitted during the trial.

Patients

COVID-19 severe or critically

Diagnosis of infection with SARSCoV-2 within 7 days prior to randomization, diagnosis of pneumonia with pulmonary infiltrates on chest x-ray or computedtomographic scan within 5 days prior to randomization, peripheral capillary oxygen saturation of 93%or less on room air or arterial oxygen partial pressure/fraction of inspired oxygen less than 300mmHg, and blood levels of CRP of 20mg/L or greater or ferritin of 600 μg/L or greater.

Method

Double-blind.

39 hospitals in Europe and the United States.

Remark